^
    5ms
    Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Jan 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    MB-103
    5ms
    TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jun 2034 --> Sep 2034 | Trial primary completion date: Jun 2028 --> Sep 2028
    Trial completion date • Trial primary completion date
    8ms
    CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Chinese PLA General Hospital
    New P1/2 trial
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • HypoSti.CAR-HER2 T
    8ms
    Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, UTC Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV
    8ms
    HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=39 --> 24 | Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Mar 2025 --> Feb 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification
    |
    MB-103
    9ms
    TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jan 2034 --> Jun 2034 | Trial primary completion date: Jan 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    10ms
    VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=45, Recruiting, Baylor College of Medicine | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    TT16
    11ms
    Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    MB-103
    11ms
    Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2024 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    MB-103
    12ms
    HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Seattle Children's Hospital | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    HER2-Specific CAR T
    1year
    A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Oct 2024
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    cyclophosphamide • CCT303-406
    1year
    Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, UTC Therapeutics Inc.
    New trial
    |
    albumin-bound paclitaxel • cyclophosphamide